The evolving role of radiotherapy in treatment of oligometastatic NSCLC.

Abstract:

:Non-small cell lung cancer (NSCLC) patients with metastases limited in site and number, termed oligometastases, may represent a unique subpopulation of advanced NSCLC with improved prognosis. The optimal management of these patients remains unclear with the treatment approach currently undergoing a paradigm shift. The potential benefit of aggressive metastasis directed local treatment with surgery and/or radiotherapy (RT) in combination with systemic therapy is bolstered predominantly by retrospective analyses but also by a growing number of non-randomized prospective studies regarding the use of ablative RT techniques including stereotactic body radiotherapy (SBRT), alternatively termed stereotactic ablative radiotherapy (SABR), directed at the primary tumor (if present) and all metastatic sites. Long-term survival is possible in a subset of patients treated aggressively in this manner. The challenge for the clinical oncology community moving forward is appropriately selecting patients for this treatment approach based on clinical, imaging, and molecular features and increasing enrollment of patients to prospective clinical trials to more definitively determine the added benefit and appropriate timing of aggressive metastasis directed therapy in the oligometastatic setting.

authors

Bergsma DP,Salama JK,Singh DP,Chmura SJ,Milano MT

doi

10.1586/14737140.2015.1105745

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

1459-71

issue

12

eissn

1473-7140

issn

1744-8328

journal_volume

15

pub_type

杂志文章,评审
  • Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations.

    abstract::Cardiac toxicity is one of the most important long-term toxicities experienced by cancer survivors so that survival rate due to anticancer therapy may be negatively affected due to cardiac complications. Thus, the search for novel methods to lower the incidence of treatment-related cardiotoxicity is a priority for all...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2015.1047766

    authors: Abdel-Rahman O,Alorabi M

    更新日期:2015-01-01 00:00:00

  • Emerging data on improving response to hormone therapy: the role of novel targeted agents.

    abstract:INTRODUCTION:Hormone receptor positive (HR+) breast cancer represents the most common subtype of breast cancer. Metastatic HR+ breast cancer may develop resistance to standard hormone therapies, arising from genomic alterations in the estrogen receptor and/or upregulation of other signal transduction pathways. Areas co...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1412259

    authors: Vidula N,Rugo HS

    更新日期:2018-01-01 00:00:00

  • Role of MRI for staging of rectal cancer.

    abstract::Total mesorectal excision has been established as a standard surgical procedure for rectal cancer. MRI is now routinely used for preoperative staging of rectal cancer and provides accurate assessment of the tumor relative to the circumferential margin, that is, the mesorectal fascia. This identifies patients at risk o...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.13

    authors: Jhaveri KS,Sadaf A

    更新日期:2009-04-01 00:00:00

  • Anticancer drug development based on modulation of the Bcl-2 family core apoptosis mechanism.

    abstract::Cancer cells generally maintain their survival by suppressing apoptosis. Mitochondrial mechanisms are involved in most forms of apoptosis (referred to as mitochondrial apoptosis), and the Bcl-2 family controls apoptosis at the mitochondrion via a balance of the effects of pro- and antiapoptotic members. Antiapoptotic ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.6.1157

    authors: Gardner CR

    更新日期:2004-12-01 00:00:00

  • Sentinel lymph node biopsy for melanoma of the head and neck.

    abstract::Since its first description nearly two centuries ago, melanoma has been a difficult disease to diagnose and treat. With the incidence and mortality rates slowly increasing, understanding this disease is more important than ever. Herein, the current diagnostic and treatment recommendations for melanoma of the head and ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.3.5.673

    authors: Lentsch EJ,McMasters KM

    更新日期:2003-10-01 00:00:00

  • Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.

    abstract::Nonseminomatous germ cell tumors of the testicle are highly treatable and curable. The evolution of cancer control for this disease has demonstrated an effective integration of medical and surgical approaches over the last 30 years. Current emphasis in the therapy of nonseminomatous germ cell tumors focuses on minimiz...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.1.75

    authors: Yoon GH,Stein JP,Skinner DG

    更新日期:2005-02-01 00:00:00

  • Update on genetic predisposition to breast cancer.

    abstract::It has been evident for some time that individuals from some families exhibit a genetic predisposition to breast cancer. Since the discovery of the first breast cancer susceptibility gene, BRCA1 in the 1990s, much work has been carried out to identify further breast cancer susceptibility genes. This has led to the ide...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.38

    authors: Ahmed M,Lalloo F,Evans DG

    更新日期:2009-08-01 00:00:00

  • Cancer of the nasal cavity and paranasal sinuses.

    abstract::Sinonasal malignancies continue to have poor survival rates. Disease-related mortality is usually the result of disease recurrence and progression at the primary site despite aggressive therapy. Complete surgical excision with postoperative radiation therapy remains the standard of care for resectable lesions. Improve...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.3.411

    authors: Maghami E,Kraus DH

    更新日期:2004-06-01 00:00:00

  • Pembrolizumab for advanced cervical cancer: safety and efficacy.

    abstract::Introduction: Pembrolizumab is an immune checkpoint inhibitor with high specificity for binding to the programmed cell death 1 (PD-1) receptor. It has been approved by the FDA in patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express the programmed ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1850279

    authors: De Felice F,Giudice E,Bolomini G,Distefano MG,Scambia G,Fagotti A,Marchetti C

    更新日期:2020-11-26 00:00:00

  • Notch signaling in lung cancer.

    abstract::Lung cancer is the leading cause of cancer-related deaths in the Western world. The lungs can be affected by a number of histologically diverse malignancies. Nonetheless, the vast majority of lung cancers are classified as non-small-cell lung cancer (NSCLC). Despite extensive research on different therapeutic regimens...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.158

    authors: Galluzzo P,Bocchetta M

    更新日期:2011-04-01 00:00:00

  • RNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells.

    abstract::Cancer immunotherapy aims at eliciting an immune response directed against tumor antigens to help fight off residual tumor cells and, thereby, improve the survival and quality of life of cancer patients. Different immunotherapeutic approaches share the use of dendritic cells (DCs) to present tumor-associated antigens ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,收录出版,评审

    doi:10.1586/14737140.9.1.97

    authors: Tyagi RK,Mangal S,Garg N,Sharma PK

    更新日期:2009-01-01 00:00:00

  • Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC.

    abstract::For many decades, the use of chemotherapy as second-line therapy in non-small-cell lung cancer relied upon disease progression. Several studies have shown that four to six cycles of chemotherapy administered as front-line therapy treatment offers a survival advantage to patients; however, further chemotherapy beyond t...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.30

    authors: Velez M,Belalcazar A,Domingo G,Blaya M,Raez LE,Santos ES

    更新日期:2010-04-01 00:00:00

  • Recent advances in the management of squamous cell carcinoma of the head and neck.

    abstract::Therapeutic outcomes of the currently used chemotherapeutic agents for recurrent or advanced head and neck squamous cell carcinoma, such as methotrexate or a combination of 5-fluorouracil and cisplatin, are far beyond satisfaction. New chemotherapeutic agents, such as taxanes, paclitaxel and docetaxel, are among the m...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.1.1.99

    authors: Kim KB,Khuri FR,Shin DM

    更新日期:2001-06-01 00:00:00

  • Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience.

    abstract:BACKGROUND:Chemotherapy-induced toxic liver injury is a relevant issue in the clinical management of patients affected with metastatic colorectal cancer (mCRC). This retrospective study evaluated patterns of liver toxicity in patients treated with FOLinic acid, Fluorouracil, IRInotecan (FOLFIRI)-based regimens. METHOD...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.2015.1061937

    authors: Vincenzi B,Imperatori M,Picardi A,Vespasiani Gentilucci U,Gallo P,Fausti V,Spalato Ceruso M,Santini D,Tonini G

    更新日期:2015-01-01 00:00:00

  • Clodronate in the prevention and treatment of skeletal metastasis.

    abstract::Many solid tumors, including breast and prostate cancer, metastasize to bone, thereby putting patients at high risk for developing skeletal complications including pathologic fracture, spinal cord compression and debilitating bone pain. Patients often live for many years after developing bone metastasis, a fact that h...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.2.221

    authors: Gulley J,Dahut WL

    更新日期:2005-04-01 00:00:00

  • Management of long bone metastases: recommendations from the Italian Orthopaedic Society bone metastasis study group.

    abstract::The purpose of this article is to outline the current approach to patients affected by metastasis to the long bones and to present a clinical and surgical algorithm available for clinicians and for future research. A modern approach to patients affected by long bone metastasis in fact requires a multidisciplinary cont...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.2014.947691

    authors: Capanna R,Piccioli A,Di Martino A,Daolio PA,Ippolito V,Maccauro G,Piana R,Ruggieri P,Gasbarrini A,Spinelli MS,Campanacci DA,Italian Orthopaedic Society Bone Metastasis Study Group.

    更新日期:2014-10-01 00:00:00

  • Primary systemic therapy in HER2-amplified breast cancer: a clinical review.

    abstract::Primary systemic therapy (PST) in early breast cancer is utilized in locally advanced breast tumors and when breast-conserving surgery is desirable. In addition, the PST setting provides an opportunity to monitor response including histopathological and biomarker examination of the tumor and host tissues before and af...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.62

    authors: Khasraw M,Bell R

    更新日期:2012-08-01 00:00:00

  • Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review.

    abstract:INTRODUCTION:A systematic review was performed to explore the health-related quality of life (HRQoL) outcomes among cancer patients receiving PD-(L)1 inhibitors compared to those receiving traditional cytotoxic therapy. Areas covered: Citations from PubMed and the American Society of Clinical Oncology meeting library w...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2018.1528146

    authors: Abdel-Rahman O,Oweira H,Giryes A

    更新日期:2018-12-01 00:00:00

  • Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies.

    abstract::Bacillus Calmette-Guérin (BCG) has been used in the intravesical treatment of urothelial bladder cancer (UBC) for three decades. Despite its efficacy, intravesical BCG therapy is associated with some limitations such as side effects and BCG failure, which have inspired multiple ways to improve it. Recent advances have...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2015.961430

    authors: Wang Y,Yang M,Yu Q,Yu L,Shao S,Wang X

    更新日期:2015-01-01 00:00:00

  • The role of surgery in recurrent endometrial cancer.

    abstract:INTRODUCTION:Endometrial cancer is a common gynecologic malignancy in the United States, and the recurrence rate depends on the disease stage at diagnosis. Recurrence can affect several areas and follow different patterns. AREAS COVERED:The role of surgery at the time of recurrence is not clearly defined. In this revi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2016.1190650

    authors: Zanfagnin V,Ferrero A,Biglia N,Aletti G,Gill SE,Makdisi PB,Multinu F,Mariani A

    更新日期:2016-07-01 00:00:00

  • Colorectal cancer: using blood samples and tumor tissue to detect K-ras mutations.

    abstract::We performed a meta-analysis to assess whether blood can be substituted for tumor tissue in K-ras mutation testing. PubMed, EMBASE, MEDLINE, and BIOSIS databases were searched. Twenty-three studies including 1261 patients were included. The pooled overall sensitivity, specificity, and concordance rate were 0.69 (95% C...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,meta分析

    doi:10.1586/14737140.2015.1037836

    authors: Li Y,Fu XH,Yuan JQ,Yang ZY,Mao C,Dong XM,Tang JL,Wang SY

    更新日期:2015-06-01 00:00:00

  • The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.

    abstract::Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) represents a distinct disease entity whose molecular phenotype predicts exquisite sensitivity to the reversible EGFR-tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. However, primary or acquired resistance to these agents remain...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1586/era.11.34

    authors: Metro G,Crinò L

    更新日期:2011-05-01 00:00:00

  • Implication of miRNA in the diagnosis and treatment of breast cancer.

    abstract::Breast cancer (BC) comprises a group of different diseases characterized by changes in tissue structure and gene expression. Recent advances in molecular biology have shed new light on the participation of genes and their products in the biology of BC. MicroRNAs (miRNAs) are small noncoding endogenous RNA molecules th...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.40

    authors: Castañeda CA,Agullo-Ortuño MT,Fresno Vara JA,Cortes-Funes H,Gomez HL,Ciruelos E

    更新日期:2011-08-01 00:00:00

  • Neoadjuvant chemotherapy in invasive bladder cancer.

    abstract::The role of neoadjuvant chemotherapy in muscle-invasive bladder cancer has been clarified by recent randomized studies and meta-analyses, which all showed that cisplatin-based, combination chemotherapy offers a significant survival advantage. Preoperative chemotherapy results in downstaging in a significant percentage...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.6.993

    authors: Bamias A,Dimopoulos MA

    更新日期:2005-12-01 00:00:00

  • Current surgical treatment of intermediate risk differentiated thyroid cancer: a systematic review.

    abstract::Introduction: Surgical treatment of thyroid cancer has become less aggressive but for many patients, the threshold for performing total thyroidectomy (TT), as opposed to thyroid lobectomy (TL), has remained unclear. Current American Thyroid Association (ATA) guidelines encourage more individualization of treatment opt...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1850280

    authors: Guo MY,Wiseman JJ,Wiseman SM

    更新日期:2020-12-15 00:00:00

  • Lymph node dissection for bladder cancer: the issue of extent and feasibility in the minimally invasive era.

    abstract::Lymph node dissection in bladder cancer is an integral part of radical cystectomy. It allows for accurate staging of the patient and will, therefore, serve to dictate additional treatment and add prognostic information. The issue of what is an adequate lymphadenectomy as to the extent and boundaries of the operation, ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.147

    authors: Ghavamian R,Hakimi AA

    更新日期:2009-12-01 00:00:00

  • Management Strategies for Recurrent Endometrial Cancer.

    abstract:INTRODUCTION:Endometrial cancer is the most common gynecologic malignancy in the developed world, and its incidence is increasing. Mortality from this cancer has not improved in recent decades and is primarily driven by high-grade carcinomas that are more likely to present at an advanced stage and ultimately are more l...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1491311

    authors: Connor EV,Rose PG

    更新日期:2018-09-01 00:00:00

  • Is axillary dissection needed in node-positive breast cancer?

    abstract::The standard of care in the management of the axilla for a woman with breast cancer was traditionally a level I and II axillary lymph node dissection (ALND). Since the pivotal studies in the mid-1990s, sentinel lymph node biopsy (SLNB) in breast carcinoma has come to replace ALND in women with clinically negative axil...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.8.2.195

    authors: Greenberg CC,Bafford AC,Golshan M

    更新日期:2008-02-01 00:00:00

  • Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.

    abstract::A large number of different 5-hydroxytryptamine (HT)(3) receptor antagonists have been marketed with the indication of preventing nausea and vomiting induced by chemotherapy--palonosetron is the most recently developed of these. Pharmacologic studies have revealed that palonosetron has a long half-life, a high affinit...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.175

    authors: Ruhlmann C,Herrstedt J

    更新日期:2010-02-01 00:00:00

  • Contralateral prophylactic mastectomy for patients with unilateral breast cancer.

    abstract::Patients with unilateral breast cancer are at increased risk of developing a second cancer in the contralateral breast. Some women choose contralateral prophylactic mastectomy (CPM) to prevent cancer in the contralateral breast. Several studies have demonstrated that CPM significantly decreases the occurrence of contr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.8.1117

    authors: Tuttle T,Habermann E,Abraham A,Emory T,Virnig B

    更新日期:2007-08-01 00:00:00